SCHEMBL25933672

SCHEMBL25933672

Cc1ccc(-c2nn(C3CCN(C4(C)CCN(C5CN(C(=O)OC(C)(C)C)C5)CC4)CC3)c3ncnc(N)c23)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.52
RET P07949 1/20 0.52
EGFR P00533 8/20 0.51
SRC P12931 5/20 0.51
PIK3CD O00329 1/20 0.51
ABL1 P00519 1/20 0.51
HCK P08631 1/20 0.51
PIK3CA P42336 1/20 0.51
PIK3CB P42338 1/20 0.51
MTOR P42345 1/20 0.51
PIK3CG P48736 1/20 0.51
EPHB4 P54760 1/20 0.51
PRKDC P78527 1/20 0.51
PI4KB Q9UBF8 1/20 0.51
BTK Q06187 7/20 0.49
LCK P06239 2/20 0.47
TEK Q02763 1/20 0.46
ITK Q08881 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25933669 0.93 EGFR (0.54) KDRRETEGFRSRCPIK3CD
SCHEMBL25933742 0.87 BTK (0.59) KDRRETEGFRSRCABL1
SCHEMBL25933728 0.87 BTK (0.59) KDRRETEGFRSRCABL1
SCHEMBL25472498 0.84 BTK (0.62) KDREGFRSRCBTKLCK
SCHEMBL25933975 0.83 EGFR (0.49) KDRRETEGFRSRCPIK3CD
SCHEMBL24197093 0.83 BTK (0.60) KDRRETEGFRSRCABL1
SCHEMBL25933740 0.82 BTK (0.60) KDREGFRSRCPIK3CDABL1
SCHEMBL25933738 0.82 BTK (0.63) KDREGFRSRCPIK3CDABL1
SCHEMBL25933966 0.82 EGFR (0.49) KDRRETEGFRSRCPIK3CD
SCHEMBL25933673 0.82 BTK (0.49) KDRRETEGFRSRCPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR BTK, WEE1, WEE2 KDR 1977/4885RET 1868/4885EGFR 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.